Deep Track Capital has made a significant move in the biotech sector by acquiring 6,772,595 shares of Alumis (NASDAQ:ALMS) for an estimated $169.31 million during Q1 2026. This transaction reflects a 2.76% increase in Deep Track’s reportable assets under management, with the new stake valued at $149.20 million at quarter-end. Alumis has seen a remarkable 355% increase in share price over the past year, far outpacing the S&P 500’s 28% gain.

The investment underscores Deep Track’s strategy of concentrating on late-stage healthcare companies with promising clinical pipelines. Alumis is advancing its lead asset, envudeucitinib, a TYK2 inhibitor for autoimmune diseases, with pivotal Phase 3 data showing promising efficacy in psoriasis. The company is on track for a New Drug Application submission later this year and anticipates critical Phase 2b lupus data soon, which could significantly impact its valuation.

For market professionals, this transaction highlights Alumis as a potential high-reward investment, contingent on the success of upcoming clinical milestones. However, any setbacks could challenge the sustainability of its current valuation.

Source: nasdaq.com